What is SPRINT trial?
The Systolic Blood Pressure Intervention Trial (SPRINT) is a 2-arm, multicenter, randomized clinical trial designed to test whether a treatment program aimed at reducing systolic blood pressure (SBP) to a lower goal than currently recommended will reduce cardiovascular disease (CVD) risk.
Why was the sprint trial stopped?
This went on for more than three years, after which the trial was stopped because of a lower rate of the primary composite cardiovascular outcome in the intensive as compared to the standard treatment patients (-25%, P ≤ 0.001).
What is the SPRINT criteria?
The guidelines define high blood pressure for adults as systolic readings of 130 mm Hg or higher or diastolic readings of 80 mm Hg or higher. This a change from the old guideline definition for high blood pressure, which was systolic readings of 140 mm Hg or higher or diastolic readings of 80 mm Hg or higher.
When was SPRINT trial conducted?
2010 to 2015
PMID 26551272. The Systolic Blood Pressure Intervention Trial (SPRINT) is a multi-center clinical trial that was performed from 2010 to 2015, and published in November 2015.
What is the Accord trial?
ACCORD is the first large clinical trial to compare the cardiovascular effects of a statin (simvastatin) and placebo, or inactive pill, to combination therapy of a statin (simvastatin) and a fibrate (fenofibrate) in high-risk adults with type 2 diabetes. The ACCORD lipid trial involved 5,518 participants.
What is Advance trial?
In the ADVANCE trial, an intensive glucose-control strategy involving gliclazide (modified release), and other drugs as required, lowered the average glycated hemoglobin value to 6.5% in a broad range of patients with type 2 diabetes and reduced the incidence of the combined primary outcome of major macrovascular or …
What is the goal blood pressure for diabetes?
Patients with diabetes mellitus — In patients with diabetes, we suggest a goal blood pressure of 120 to 125/<80 mmHg (using the non-routine [preferred] measurement methods including standardized office-based measurement, AOBPM, home blood pressure, and ABPM) or 125 to 130/<80 mmHg (using routine office measurements).
What is the recommended requirement for blood pressure based on the sprint trials?
The SPRINT trial showed that intensive BP control to SBP <120 mm Hg results in significant cardiovascular benefit in high-risk patients with hypertension compared with routine BP control to <140 mm Hg.
What is blood pressure in detail?
The force of circulating blood on the walls of the arteries. Blood pressure is taken using two measurements: systolic (measured when the heart beats, when blood pressure is at its highest) and diastolic (measured between heart beats, when blood pressure is at its lowest).
How was blood pressure measured in the Sprint Trial?
Abstract. The SPRINT trial was a landmark study and appeared to set new aggressive goals for the treatment of hypertension. It relied upon an average of multiple blood pressure measurements taken with an automated blood pressure cuff with a noted cool-down period beforehand.
How many clinical sites does Sprint have?
The SPRINT trial was conducted from November 2010 until August 2015 in 102 clinical sites organized into 5 Clinical Center Networks.
What was the main research question in the sprint study?
Cardiovascular: The main cardiovascular research question in SPRINT was to understand whether treating high blood pressure to a target systolic blood pressure goal of less than 120 mm Hg was better than treating to a goal of less than 140 mm Hg, which was the commonly recommended target at the time the SPRINT study was initiated.
What is the NIH systolic blood pressure intervention trial (sprint)?
The NIH Systolic Blood Pressure Intervention Trial (SPRINT), an NHLBI-supported study, was designed to answer three important research questions about how treating to a lower systolic blood pressure target—less than 120 millimeters of mercury (mm Hg)—affects the cardiovascular system, kidneys, and brain.
What does sprint stand for?
The 2015 Systolic Blood Pressure Intervention Trial (SPRINT) studied 9,361 non-diabetic patients ≥50 years of age without a history of prior stroke who were at elevated risk for CV events. Patients were randomized to intensive BP control targeting SBP <120 mm Hg or to standard therapy targeting SBP 135-139 mm Hg.
What is the latest follow-up from the sprint study?
Additional 1-year follow-up from SPRINT was published in 2021, without any major changes in the observed findings. [4]